HIF Gene Expression in Cancer Therapy

Methods in Enzymology

Volumn 435, Issue , 2007, Pages 323-345

  Chan, Denise A ^a   Krieg, Adam J ^a   Turcotte, Sandra ^a   Giaccia, Amato J ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 [BIS(2 CHLOROETHYL)OXIDOAMINO]PHENYLALANINE; ANTIMYCIN A1; ANTINEOPLASTIC AGENT; BORTEZOMIB; CHEMOTIN; ECHINOMYCIN; GELDANAMYCIN; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR INHIBITOR; IMATINIB; LONAFARNIB; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NELFINAVIR; NOSCAPINE; NSC 134754; NSC 643735; NSC 644221; OLIGOMYCIN; PACLITAXEL; PLEUROTIN; PX 12; QUINOCAMYCIN; TANESPIMYCIN; TEMSIROLIMUS; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE; WORTMANNIN;

BINDING KINETICS; BINDING SITE; CANCER THERAPY; CHROMATIN IMMUNOPRECIPITATION; GENE ACTIVITY; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC TRANSCRIPTION; HUMAN; HYDROXYLATION; HYPOXIA; KNOCKOUT MOUSE; MICROARRAY ANALYSIS; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; REVIEW; RNA ANALYSIS; RNA INTERFERENCE; SOMATIC CELL; TRANSCRIPTION REGULATION; WESTERN BLOTTING; ANIMAL; DRUG ANTAGONISM; GENETIC PROCEDURES; GENETICS; MOUSE; MOUSE MUTANT; NEOPLASM;

ANIMALS; GENE EXPRESSION; GENETIC TECHNIQUES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; MICE; MICE, KNOCKOUT; NEOPLASMS;

EID: 39749099312     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0076-6879(07)35016-7     Document Type: Review

References (113)

1. Bardos J.I., and Ashcroft M. Hypoxia-inducible factor-1 and oncogenic signaling. Bioessays 26 (2004) 262-269
2. Belozerov V.E., and Van Meir E.G. Hypoxia inducible factor-1: A novel target for cancer therapy. Anticancer Drugs 16 (2005) 901-909
3. Berra E., Pages G., and Pouyssegur J. MAP kinases and hypoxia in the control of VEGF expression. Cancer Metastasis Rev. 19 (2000) 139-145
4. Berra E., Benizri E., Ginouves A., Volmat V., Roux D., and Pouyssegur J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1α in normoxia. EMBO J. 22 (2003) 4082-4090
5. Bindra R.S., and Glazer P.M. Genetic instability and the tumor microenvironment: Towards the concept of microenvironment-induced mutagenesis. Mutat. Res. 569 (2005) 75-85
6. Bindra R.S., and Glazer P.M. Co-repression of mismatch repair gene expression by hypoxia in cancer cells: Role of the Myc/Max network. Cancer Lett. 252 (2007) 93-103
7. Birle D.C., and Hedley D.W. Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors. Cancer Res. 67 (2007) 1735-1743
8. Blancher C., Moore J.W., Robertson N., and Harris A.L. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1α, HIF-2α, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3′-kinase/Akt signaling pathway. Cancer Res. 61 (2001) 7349-7355
9. Bracken C.P., Fedele A.O., Linke S., Balrak W., Lisy K., Whitelaw M.L., and Peet D.J. Cell-specific regulation of hypoxia-inducible factor (HIF)-1α and HIF-2α stabilization and transactivation in a graded oxygen environment. J. Biol. Chem. 281 (2006) 22575-22585
10. Brugarolas J.B., Vazquez F., Reddy A., Sellers W.R., and Kaelin Jr. W.G. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 4 (2003) 147-158
11. Bruick R.K., and McKnight S.L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294 (2001) 1337-1340
12. Carmeliet P., Dor Y., Herbert J.M., Fukumura D., Brusselmans K., Dewerchin M., Neeman M., Bono F., Abramovitch R., Maxwell P., Koch C.J., Ratcliffe P., et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394 (1998) 485-490
13. Ceradini D.J., Kulkarni A.R., Callaghan M.J., Tepper O.M., Bastidas N., Kleinman M.E., Capla J.M., Galiano R.D., Levine J.P., and Gurtner G.C. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat. Med. 10 (2004) 858-864
14. Chan D.A., Sutphin P.D., Denko N.C., and Giaccia A.J. Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1alpha. J. Biol. Chem. 277 (2002) 40112-40117
15. Chan D.A., Sutphin P.D., Yen S.E., and Giaccia A.J. Coordinate regulation of the oxygen-dependent degradation domains of hypoxia-inducible factor 1 alpha. Mol. Cell Biol. 25 (2005) 6415-6426
16. 2 sensing. J. Biol. Chem. 275 (2000) 25130-25138
17. Chau N.M., Rogers P., Aherne W., Carroll V., Collins I., McDonald E., Workman P., and Ashcroft M. Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1alpha induction in response to hypoxic stress and growth factors. Cancer Res. 65 (2005) 4918-4928
18. Chen C., Pore N., Behrooz A., Ismail-Beigi F., and Maity A. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J. Biol. Chem. 276 (2001) 9519-9525
19. Chun Y.S., Yeo E.J., Choi E., Teng C.M., Bae J.M., Kim M.S., and Park J.W. Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochem. Pharmacol. 61 (2001) 947-954
20. Comerford K.M., Wallace T.J., Karhausen J., Louis N.A., Montalto M.C., and Colgan S.P. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 62 (2002) 3387-3394
21. Creighton-Gutteridge M., Cardellina II J.H., Stephen A.G., Rapisarda A., Uranchimeg B., Hite K., Denny W.A., Shoemaker R.H., and Melillo G. Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation by NSC 644221. Clin. Cancer Res. 13 (2007) 1010-1018
22. Dang D.T., Chen F., Gardner L.B., Cummins J.M., Rago C., Bunz F., Kantsevoy S.V., and Dang L.H. Hypoxia-inducible factor-1alpha promotes nonhypoxia-mediated proliferation in colon cancer cells and xenografts. Cancer Res. 66 (2006) 1684-1936
23. Davidson T.L., Chen H., Di Toro D.M., D'Angelo G., and Costa M. Soluble nickel inhibits HIF-prolyl-hydroxylases creating persistent hypoxic signaling in A549 cells. Mol. Carcinog. 45 (2006) 479-489
24. Denko N.C., Fontana L.A., Hudson K.M., Sutphin P.D., Raychaudhuri S., Altman R., and Giaccia A.J. Investigating hypoxic tumor physiology through gene expression patterns. Oncogene 22 (2003) 5907-5914
25. Epstein A.C., Gleadle J.M., McNeill L.A., Hewitson K.S., O'Rourke J., Mole D.R., Mukherji M., Metzen E., Wilson M.I., Dhanda A., Tian Y.M., Masson N., et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107 (2001) 43-54
26. Erler J.T., Bennewith K.L., Nicolau M., Dornhofer N., Kong C., Le Q.T., Chi J.T., Jeffrey S.S., and Giaccia A.J. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440 (2006) 1222-1226
27. Fath D.M., Kong X., Liang D., Lin Z., Chou A., Jiang Y., Fang J., Caro J., and Sang N. Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-α. J. Biol. Chem. 281 (2006) 13612-13619
28. Gao N., Shen L., Zhang Z., Leonard S.S., He H., Zhang X.G., Shi X., and Jiang B.H. Arsenite induces HIF-1α and VEGF through PI3K, Akt and reactive oxygen species in DU145 human prostate carcinoma cells. Mol. Cell Biochem. 255 (2004) 33-45
29. Gao N., Ding M., Zheng J.Z., Zhang Z., Leonard S.S., Liu K.J., Shi X., and Jiang B.H. Vanadate-induced expression of hypoxia-inducible factor 1 alpha and vascular endothelial growth factor through phosphatidylinositol 3-kinase/Akt pathway and reactive oxygen species. J. Biol. Chem. 277 (2002) 31963-31971
30. Gao N., Jiang B.H., Leonard S.S., Corum L., Zhang Z., Roberts J.R., Antonini J., Zheng J.Z., Flynn D.C., Castranova V., and Shi X. p38 signaling-mediated hypoxia-inducible factor 1alpha and vascular endothelial growth factor induction by Cr(VI) in DU145 human prostate carcinoma cells. J. Biol. Chem. 277 (2002) 45041-45048
31. Giaccia A., Siim B.G., and Johnson R.S. HIF-1 as a target for drug development. Nat. Rev. Drug Discov. 2 (2003) 803-811
32. Gong Y., and Agani F.H. Oligomycin inhibits HIF-1α expression in hypoxic tumor cells. Am. J. Physiol. Cell Physiol. 288 (2005) C1023-C1029
33. Gu Y.Z., Moran S.M., Hogenesch J.B., Wartman L., and Bradfield C.A. Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF-3α. Gene Expr. 7 (1998) 205-213
34. Han J.Y., Oh S.H., Morgillo F., Myers J.N., Kim E., Hong W.K., and Lee H.Y. Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer. J. Natl. Cancer Inst. 97 (2005) 1272-1286
35. Hewitson K.S., McNeill L.A., Riordan M.V., Tian Y.M., Bullock A.N., Welford R.W., Elkins J.M., Oldham N.J., Bhattacharya S., Gleadle J.M., Ratcliffe P.J., Pugh C.W., et al. Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J. Biol. Chem. 277 (2002) 26351-26355
36. Hu C.J., Wang L.Y., Chodosh L.A., Keith B., and Simon M.C. Differential roles of hypoxia-inducible factor 1alpha (HIF-1α) and HIF-2α in hypoxic gene regulation. Mol. Cell Biol. 23 (2003) 9361-9374
37. Huang L.E., Bindra R.S., Glazer P.M., and Harris A.L. Hypoxia-induced genetic instability-a calculated mechanism underlying tumor progression. J. Mol. Med. 85 (2007) 139-148
38. Hudson C.C., Liu M., Chiang G.G., Otterness D.M., Loomis D.C., Kaper F., Giaccia A.J., and Abraham R.T. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol. Cell Biol. 22 (2002) 7004-7014
39. Isaacs J.S., Jung Y.J., Mimnaugh E.G., Martinez A., Cuttitta F., and Neckers L.M. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J. Biol. Chem. 277 (2002) 29936-29944
40. 2 sensing. Science 292 (2001) 464-468
41. 2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev. 12 (1998) 149-162
42. 2-regulated prolyl hydroxylation. Science 292 (2001) 468-472
43. Jiang B.H., Agani F., Passaniti A., and Semenza G.L. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: Involvement of HIF-1 in tumor progression. Cancer Res. 57 (1997) 5328-5335
44. Jiang B.H., Jiang G., Zheng J.Z., Lu Z., Hunter T., and Vogt P.K. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ. 12 (2001) 363-369
45. Katschinski D.M., Le L., Heinrich D., Wagner K.F., Hofer T., Schindler S.G., and Wenger R.H. Heat induction of the unphosphorylated form of hypoxia-inducible factor-1alpha is dependent on heat shock protein-90 activity. J. Biol. Chem. 277 (2002) 9262-9267
46. Kong D., Park E.J., Stephen A.G., Calvani M., Cardellina J.H., Monks A., Fisher R.J., Shoemaker R.H., and Melillo G. Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res. 65 (2005) 9047-9055
47. Kong X., Lin Z., Liang D., Fath D., Sang N., and Caro J. Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol. Cell Biol. 26 (2006) 2019-2028
48. Koong A.C., Denko N.C., Hudson K.M., Schindler C., Swiersz L., Koch C., Evans S., Ibrahim H., Le Q.T., Terris D.J., and Giaccia A.J. Candidate genes for the hypoxic tumor phenotype. Cancer Res. 60 (2000) 883-887
49. Koshiji M., To K.K., Hammer S., Kumamoto K., Harris A.L., Modrich P., and Huang L.E. HIF-1α induces genetic instability by transcriptionally down-regulating MutSα expression. Mol. Cell 17 (2005) 793-803
50. Krieg A.J., Krieg S.A., Ahn B.S., and Shapiro D.J. Interplay between estrogen response element sequence and ligands controls in vivo binding of estrogen receptor to regulated genes. J. Biol. Chem. 279 (2004) 5025-5034
51. Kung A.L., Wang S., Klco J.M., Kaelin W.G., and Livingston D.M. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat. Med. 6 (2000) 1335-1340
52. Kung A.L., Zabludoff S.D., France D.S., Freedman S.J., Tanner E.A., Vieira A., Cornell-Kennon S., Lee J., Wang B., Wang J., Memmert K., Naegeli H.U., et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 6 (2004) 33-43
53. Lal A., Peters H., St Croix B., Haroon Z.A., Dewhirst M.W., Strausberg R.L., Kaanders J.H., van der Kogel A.J., and Riggins G.J. Transcriptional response to hypoxia in human tumors. J. Natl. Cancer Inst. 93 (2001) 1337-1343
54. Lando D., Peet D.J., Gorman J.J., Whelan D.A., Whitelaw M.L., and Bruick R.K. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 16 (2002) 1466-1471
55. Lando D., Peet D.J., Whelan D.A., Gorman J.J., and Whitelaw M.L. Asparagine hydroxylation of the HIF transactivation domain: a hypoxic switch. Science 295 (2002) 858-861
56. Li J., Davidson G., Huang Y., Jiang B.H., Shi X., Costa M., and Huang C. Nickel compounds act through phosphatidylinositol-3-kinase/Akt-dependent, p70(S6k)-independent pathway to induce hypoxia inducible factor transactivation and Cap43 expression in mouse epidermal Cl41 cells. Cancer Res. 64 (2004) 94-101
57. Liao D., Corle C., Seagroves T.N., and Johnson R.S. Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res. 67 (2007) 563-572
58. Litz J., and Krystal G.W. Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1alpha activity and vascular endothelial growth factor expression in small cell lung cancer cells. Mol. Cancer Ther. 5 (2006) 1415-1422
59. Liu M.Y., Poellinger L., and Walker C.L. Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene. Cancer Res. 63 (2003) 2675-2680
60. Mabjeesh N.J., Escuin D., LaVallee T.M., Pribluda V.S., Swartz G.M., Johnson M.S., Willard M.T., Zhong H., Simons J.W., and Giannakakou P. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3 (2003) 363-375
61. Maeda M., Hasebe Y., Egawa K., Shibanuma M., and Nose K. Inhibition of angiogenesis and HIF-1α activity by antimycin A1. Biol. Pharm. Bull. 29 (2006) 1344-1348
62. Mahon P.C., Hirota K., and Semenza G.L. FIH-1: A novel protein that interacts with HIF-1α and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 15 (2001) 2675-2686
63. Makino Y., Kanopka A., Wilson W.J., Tanaka H., and Poellinger L. Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3alpha locus. J. Biol. Chem. 277 (2002) 32405-32408
64. Makino Y., Cao R., Svensson K., Bertilsson G., Asman M., Tanaka H., Cao Y., Berkenstam A., and Poellinger L. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 414 (2001) 550-554
65. Maltepe E., Schmidt J.V., Baunoch D., Bradfield C.A., and Simon M.C. Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature 386 (1997) 403-407
66. Masson N., Willam C., Maxwell P.H., Pugh C.W., and Ratcliffe P.J. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J. 20 (2001) 5197-5206
67. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., Wykoff C.C., Pugh C.W., Maher E.R., and Ratcliffe P.J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
68. Mazure N.M., Chen E.Y., Laderoute K.R., and Giaccia A.J. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 90 (1997) 3322-3331
69. Mazure N.M., Chen E.Y., Yeh P., Laderoute K.R., and Giaccia A.J. Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res. 56 (1996) 3436-3440
70. McNeill L.A., Hewitson K.S., Claridge T.D., Seibel J.F., Horsfall L.E., and Schofield C.J. Hypoxia-inducible factor asparaginyl hydroxylase (FIH-1) catalyses hydroxylation at the β-carbon of asparagine-803. Biochem. J. 367 (2002) 571-575
71. Melillo G. Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol. Cancer Res. 4 (2006) 601-605
72. Minet E., Michel G., Mottet D., Raes M., and Michiels C. Transduction pathways involved in hypoxia-inducible factor-1 phosphorylation and activation. Free Radic. Biol. Med. 31 (2001) 847-855
73. Mottet D., Dumont V., Deccache Y., Demazy C., Ninane N., Raes M., and Michiels C. Regulation of hypoxia-inducible factor-1alpha protein level during hypoxic conditions by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3β pathway in HepG2 cells. J. Biol. Chem. 278 (2003) 31277-31285
74. Newcomb E.W., Lukyanov Y., Schnee T., Ali M.A., Lan L., and Zagzag D. Noscapine inhibits hypoxia-mediated HIF-1alpha expression and angiogenesis in vitro: A novel function for an old drug. Int. J. Oncol. 28 (2006) 1121-1130
75. Ohh M., Park C.W., Ivan M., Hoffman M.A., Kim T.Y., Huang L.E., Pavletich N., Chau V., and Kaelin W.G. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat. Cell Biol. 2 (2000) 423-427
76. Park S.K., Dadak A.M., Haase V.H., Fontana L., Giaccia A.J., and Johnson R.S. Hypoxia-induced gene expression occurs solely through the action of hypoxia-inducible factor 1alpha (HIF-1α): Role of cytoplasmic trapping of HIF-2α. Mol. Cell Biol. 23 (2003) 4959-4971
77. Pore N., Gupta A.K., Cerniglia G.J., Jiang Z., Bernhard E.J., Evans S.M., Koch C.J., Hahn S.M., and Maity A. Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: Implications for radiotherapy. Cancer Res. 66 (2006) 9252-9259
78. Rak J., Mitsuhashi Y., Bayko L., Filmus J., Shirasawa S., Sasazuki T., and Kerbel R.S. Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis. Cancer Res. 55 (1995) 4575-4580
79. Rapisarda A., Uranchimeg B., Scudiero D.A., Selby M., Sausville E.A., Shoemaker R.H., and Melillo G. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res. 62 (2002) 4316-4324
80. Richard D.E., Berra E., and Pouyssegur J. Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle cells. J. Biol. Chem. 275 (2000) 26765-26771
81. Richard D.E., Berra E., Gothie E., Roux D., and Pouyssegur J. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1α) and enhance the transcriptional activity of HIF-1. J. Biol. Chem. 274 (1999) 32631-32637
82. Ryan H.E., Lo J., and Johnson R.S. HIF-1α is required for solid tumor formation and embryonic vascularization. EMBO J. 17 (1998) 3005-3015
83. Salceda S., and Caro J. Hypoxia-inducible factor 1alpha (HIF-1α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J. Biol. Chem. 272 (1997) 22642-22647
84. Sandau K.B., Fandrey J., and Brune B. Accumulation of HIF-1α under the influence of nitric oxide. Blood 97 (2001) 1009-1015
85. Scandurro A.B., Weldon C.W., Figueroa Y.G., Alam J., and Beckman B.S. Gene microarray analysis reveals a novel hypoxia signal transduction pathway in human hepatocellular carcinoma cells. Int. J. Oncol. 19 (2001) 129-135
86. -/- mice. Nat. Genet. 35 (2003) 331-340
87. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3 (2003) 721-732
88. Semenza G.L., Nejfelt M.K., Chi S.M., and Antonarakis S.E. Hypoxia-inducible nuclear factors bind to an enhancer element located 3′ to the human erythropoietin gene. Proc. Natl. Acad. Sci. USA 88 (1991) 5680-5684
89. Skinner H.D., Zhong X.S., Gao N., Shi X., and Jiang B.H. Arsenite induces p70S6K1 activation and HIF-1α expression in prostate cancer cells. Mol. Cell Biochem. 255 (2004) 19-23
90. Sodhi A., Montaner S., Miyazaki H., and Gutkind J.S. MAPK and Akt act cooperatively but independently on hypoxia inducible factor-1alpha in rasV12 upregulation of VEGF. Biochem. Biophys. Res. Commun. 287 (2001) 292-300
91. Srinivas V., Zhang L.P., Zhu X.H., and Caro J. Characterization of an oxygen/redox-dependent degradation domain of hypoxia-inducible factor alpha (HIF-α) proteins. Biochem. Biophys. Res. Commun. 260 (1999) 557-561
92. Staller P., Sulitkova J., Lisztwan J., Moch H., Oakeley E.J., and Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 425 (2003) 307-311
93. Sugawara J., Tazuke S.I., Suen L.F., Powell D.R., Kaper F., Giaccia A.J., and Giudice L.C. Regulation of insulin-like growth factor-binding protein 1 by hypoxia and 3′, 5′-cyclic adenosine monophosphate is additive in HepG2 cells. J. Clin. Endocrinol. Metab. 85 (2000) 3821-3827
94. Sutphin P.D., Chan D.A., and Giaccia A.J. Dead cells don't form tumors: HIF-dependent cytotoxins. Cell Cycle 3 (2004) 160-163
95. Tan C., de Noronha R.G., Roecker A.J., Pyrzynska B., Khwaja F., Zhang Z., Zhang H., Teng Q., Nicholson A.C., Giannakakou P., Zhou W., Olson J.J., et al. Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res. 65 (2005) 605-612
96. Tian H., McKnight S.L., and Russell D.W. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev. 11 (1997) 72-82
97. Tian H., Hammer R.E., Matsumoto A.M., Russell D.W., and McKnight S.L. The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev. 12 (1998) 3320-3324
98. Treins C., Giorgetti-Peraldi S., Murdaca J., Semenza G.L., and Van Obberghen E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J. Biol. Chem. 277 (2002) 27975-27981
99. Wang G.L., and Semenza G.L. Purification and characterization of hypoxia-inducible factor 1. J. Biol. Chem. 270 (1995) 1230-1237
100. Wang V., Davis D.A., Haque M., Huang L.E., and Yarchoan R. Differential gene up-regulation by hypoxia-inducible factor-1alpha and hypoxia-inducible factor-2alpha in HEK293T cells. Cancer Res. 65 (2005) 3299-3306
101. Warnecke C., Zaborowska Z., Kurreck J., Erdmann V.A., Frei U., Wiesener M., and Eckardt K.U. Differentiating the functional role of hypoxia-inducible factor (HIF)-1alpha and HIF-2α (EPAS-1) by the use of RNA interference: Erythropoietin is a HIF-2α target gene in Hep3B and Kelly cells. FASEB J. 18 (2004) 1462-1464
102. Wartenberg M., Ling F.C., Muschen M., Klein F., Acker H., Gassmann M., Petrat K., Putz V., Hescheler J., and Sauer H. Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. FASEB J. 17 (2003) 503-505
103. Welford S.M., Bedogni B., Gradin K., Poellinger L., Broome Powell M., and Giaccia A.J. HIF1α delays premature senescence through the activation of MIF. Genes Dev. 20 (2006) 3366-3371
104. Welsh S., Williams R., Kirkpatrick L., Paine-Murrieta G., and Powis G. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol. Cancer Ther. 3 (2004) 233-244
105. Welsh S.J., Bellamy W.T., Briehl M.M., and Powis G. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res. 62 (2002) 5089-5095
106. Welsh S.J., Williams R.R., Birmingham A., Newman D.J., Kirkpatrick D.L., and Powis G. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Mol. Cancer Ther. 2 (2003) 235-243
107. Wiesener M.S., Turley H., Allen W.E., Willam C., Eckardt K.U., Talks K.L., Wood S.M., Gatter K.C., Harris A.L., Pugh C.W., Ratcliffe P.J., and Maxwell P.H. Induction of endothelial PAS domain protein-1 by hypoxia: Characterization and comparison with hypoxia-inducible factor-1alpha. Blood 92 (1998) 2260-2268
108. Wykoff C.C., Pugh C.W., Maxwell P.H., Harris A.L., and Ratcliffe P.J. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene 19 (2000) 6297-6305
109. Yasinska I.M., and Sumbayev V.V. S-nitrosation of Cys-800 of HIF-1α protein activates its interaction with p300 and stimulates its transcriptional activity. FEBS Lett. 549 (2003) 105-109
110. Yu F., White S.B., Zhao Q., and Lee F.S. HIF-1α binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc. Natl. Acad. Sci. USA 98 (2001) 9630-9635
111. Zhong H., Willard M., and Simons J. NS398 reduces hypoxia-inducible factor (HIF)-1alpha and HIF-1 activity: Multiple-level effects involving cyclooxygenase-2 dependent and independent mechanisms. Int. J. Cancer 112 (2004) 585-595
112. Zhong H., Chiles K., Feldser D., Laughner E., Hanrahan C., Georgescu M.M., Simons J.W., and Semenza G.L. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics. Cancer Res. 60 (2000) 1541-1545
113. Zundel W., Schindler C., Haas-Kogan D., Koong A., Kaper F., Chen E., Gottschalk A.R., Ryan H.E., Johnson R.S., Jefferson A.B., Stokoe D., and Giaccia A.J. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 14 (2000) 391-396